Skip to main content
OpenTrials

Clinical trial condition

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells

Explore clinical trials studying Blasts More Than 5 Percent of Bone Marrow Nucleated Cells. Study availability and eligibility vary by location and protocol.

4 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells trial results

Recruiting

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

NCT03801434

Conditions
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, +17 more
Locations
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • OHSU Knight Cancer Institute Portland, Oregon, United States
  • University of Utah Salt Lake City, Utah, United States
  • Fred Hutchinson cancer research center Seattle, Washington, United States
View Trial Details

Related conditions